Chapman University

Chapman University Digital Commons
Biology, Chemistry, and Environmental Sciences
Faculty Articles and Research

Science and Technology Faculty Articles and
Research

10-19-2022

Effects of Cannabinoids on Ligand-gated Ion Channels
Murat Oz
Keun-Hang Susan Yang
Mohamed Omer Mahgoub

Follow this and additional works at: https://digitalcommons.chapman.edu/sees_articles
Part of the Medical Biochemistry Commons, and the Medicinal-Pharmaceutical Chemistry Commons

Effects of Cannabinoids on Ligand-gated Ion Channels
Comments
This article was originally published in Frontiers in Physiology, volume 13, in 2022. https://doi.org/
10.3389/fphys.2022.1041833

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Copyright
The authors

Review
19 October 2022
10.3389/fphys.2022.1041833

TYPE

PUBLISHED
DOI

OPEN ACCESS

Effects of cannabinoids on
ligand-gated ion channels

EDITED BY

Mohammad-Reza Ghovanloo,
Yale University, United States
REVIEWED BY

Kenneth B. Walsh,
University of South Carolina,
United States
Seungwoo Kang,
Medical College of Georgia at Augusta
University, United States

Murat Oz 1*, Keun-Hang Susan Yang 2 and
Mohamed Omer Mahgoub 3
1
Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Kuwait University, Kuwait City,
Kuwait, 2Department of Biological Sciences, Schmid College of Science and Technology, Chapman
University, One University Drive, Orange, CA, United States, 3Department of Health and Medical
Sciences, Khawarizmi International College, Abu Dhabi, UAE

*CORRESPONDENCE

Murat Oz,
ahmet.oz@ku.edu.kw
SPECIALTY SECTION

This article was submitted to Membrane
Physiology and Membrane Biophysics,
a section of the journal
Frontiers in Physiology
11 September 2022
06 October 2022
PUBLISHED 19 October 2022
RECEIVED

ACCEPTED

CITATION

Oz M, Yang K-HS and Mahgoub MO
(2022), Effects of cannabinoids on
ligand-gated ion channels.
Front. Physiol. 13:1041833.
doi: 10.3389/fphys.2022.1041833
COPYRIGHT

© 2022 Oz, Yang and Mahgoub. This is
an open-access article distributed
under the terms of the Creative
Commons Attribution License (CC BY).
The use, distribution or reproduction in
other forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution
or reproduction is permitted which does
not comply with these terms.

Phytocannabinoids such as Δ9-tetrahydrocannabinol and cannabidiol,
endocannabinoids such as N-arachidonoylethanolamine (anandamide) and
2-arachidonoylglycerol, and synthetic cannabinoids such as CP47,497 and
JWH-018 constitute major groups of structurally diverse cannabinoids.
Along with these cannabinoids, CB1 and CB2 cannabinoid receptors and
enzymes involved in synthesis and degradation of endocannabinoids
comprise the major components of the cannabinoid system. Although,
cannabinoid receptors are known to be involved in anti-convulsant, antinociceptive, anti-psychotic, anti-emetic, and anti-oxidant effects of
cannabinoids, in recent years, an increasing number of studies suggest that,
at pharmacologically relevant concentrations, these compounds interact with
several molecular targets including G-protein coupled receptors, ion channels,
and enzymes in a cannabinoid-receptor independent manner. In this report, the
direct actions of endo-, phyto-, and synthetic cannabinoids on the functional
properties of ligand-gated ion channels and the plausible mechanisms
mediating these effects were reviewed and discussed.
KEYWORDS

cannabinoids, endocannabinoids, synthetic cannabinoids, ligand-gated ion channels,
ion channels

Introduction
Cannabis sativa plant (marijuana) consists of more than 500 chemical compounds,
and about 120 of them are structurally related phytocannabinoids which are terpenophenolic compounds chemically related to the terpenes with their ring structure derived
from a geranyl pyrophosphate (ElSohly et al., 2017). Among these phytocannabinoids, Δ9tetrahydrocannabinol (THC) and cannabidiol (CBD) are major psychoactive and nonpsychoactive components of marijuana, respectively (Izzo et al., 2009).
Following structural characterization of series of phytocannabinoids in 1960s,
CB1 and CB2 cannabinoid (CB) receptors, and endocannabinoids anandamide
(N-arachidonoylethanolamine; AEA) and 2-arachidonoylglycerol (2-AG) were
identiﬁed and shown to activate CB1 and CB2 with high afﬁnity and efﬁcacy (Devane
et al., 1992; Mechoulam et al., 1995; Cristino et al., 2020). Subsequently, enzymes involved
in synthesis and inactivation of endocannabinoids were identiﬁed. Synthesis of AEA and
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effect is not altered by CB1 and CB2 antagonists (Di Marzo et al.,
2000). THC and AEA-induced analgesic effects in hot-plate (for
AEA) and tail ﬂick tests (for THC) remain intact in CB1 knockout (Zimmer et al., 1999; Di Marzo et al., 2000) or both CB1 and
CB2 knock-out mice (Rácz et al., 2008). Similarly, AEA still
induces catalepsy and analgesia and decreases spontaneous
activity in CB1-deﬁcient mice (Di Marzo et al., 1994; Baskﬁeld
et al., 2004) and exert CB1 antagonist-resistant behavioral effects
in the open-ﬁeld test (Järbe et al., 2003a; Järbe et al., 2003b).
In neuronal systems, fast signal transmission between pre
and post synaptic structures is carried out by the conformational
changes induced by the signaling molecules, neurotransmitters in
integral membrane proteins coined ligand-gated ion channels
(LGICs). The LGICs are divided into three super families: the
Cys-loop superfamily, the glutamate receptors [NMDA
(N-methyl-D-aspartate),
AMPA
(α-amino-3-hydroxy-5methyl-4-isoxazolepropionic acid) and kainate], and the ATPgated channels (Alexander et al., 2017). The Cys-loop
superfamily comprises both cationic receptors such as
nicotinic acetylcholine (nACh) and 5-HT3 receptors and
anionic receptors such as GABA (γ -aminobutyric acid) type
A (GABAA), and glycine receptors. Typical LGIC is composed of
multiple subunits in homo or hetero pentameric structure with a
pore forming α subunit that allows the regulated ﬂow of ions
across the plasma membrane in response to binding of
endogenous or exogenous molecules. Structurally, an αsubunit of LGIC contains a large extracellular N-terminus,
four transmembrane (TM) domains, a short extracellular
C-terminus, and a large cytoplasmic domain between
TM3 and TM4 (Plested, 2016). While this review focuses on
the direct cannabinoid receptor-independent effects of
cannabinoids on the LGICs, the effects of these compounds
on other ion channels, various G-protein coupled receptors,
enzymes, and neurotransmitter transporters have been
reviewed in earlier reports (Oz, 2006; Pertwee et al., 2010;
Soderstrom et al., 2017; Cifelli et al., 2020; Senn et al., 2020;
Vitale et al., 2021).

other
N-acylethanolamines
is
catalyzed
by
N-acylphosphatidylethanolamine
(NAPE)-speciﬁc
phospholipase
D-like
hydrolase
(NAPE-PLD),
and
biosynthesis of 2-AG and other monoacylglycerols are
catalyzed by Diacylglycerol lipase α (DAGLα) and DAGLβ.
On the other hand, while anandamide and other
N-acylethanolamines are hydrolyzed by fatty acid amide
hydrolase (FAAH), the hydrolysis of 2-AG and other
monoacylglcerols catalyzed by monoacylglycerol lipase
(MAGL) (Fowler et al., 2017; Cristino et al., 2020). This
system of endogenous ligands, receptors and metabolic
enzymes became known as the endocannabinoid system. In
addition to phyto- and endocannabinoids, intensive structureactivity studies to synthetize novel high-afﬁnity ligands for
cannabinoid receptors have resulted in emergence of several
compounds
such
as
WIN55,212-2,
HU210,
and
CP55,940 with signiﬁcantly diverse chemical structures that
constitute third group of cannabinoids collectively coined
synthetic cannabinoids (Huffman and Padgett, 2005; Wiley
et al., 2014; Le Boisselier et al., 2017; Howlett et al., 2021).
In recent years, lack of psychoactive effects of some
phytocannabinoids such as CBD, increased access to cannabis
products due to decriminalization of medical use of cannabis in
several western countries, and new approvals for clinical use of
cannabinoid-based compounds have revitalized the interest in
pharmacological effects of phytocannabinoids, speciﬁcally the
CBD. In clinical practice, Nabilone (Cesamet), a synthetic
cannabinoid, and Dronabinol (Marinol), synthetic (-)
enantiomer of THC, have been used for treatment of anorexia
and chemotherapy-induced nausea and vomiting in the
United States, Canada, and United Kingdom (Wright and
Guy, 2014; Pagano et al., 2022). Nabiximols (Sativex), an oral
spray containing CBD and THC in a 1: 1 ratio, has been approved
in several countries including United Kingdom, European
Union, and Canada for the treatment of multiple sclerosisassociated spasticity (Ortiz et al., 2022; Pagano et al., 2022).
CBD has been recently approved in the United States and the
European Union as an add-on antiepileptic drug (Epidiolex) for
the treatment of patients affected by refractory epilepsy such as
Dravet syndrome and Lennox–Gastaut syndrome (Ortiz et al.,
2022; Pagano et al., 2022) and caused resurgence of interest in the
pharmacology
of
cannabinoids
in
general
and
phytocannabinoids in particular.
Since CBD does not activate CB1 and CB2 receptors, some of
the attention in cannabinoid research has recently been focused
on CB1 and CB2-independent cellular and molecular targets for
CBD and other phytocannabinoids such as cannabigerol and
cannabidivarin (Ghovanloo et al., 2022; Isaev et al., 2022; Mirlohi
et al., 2022). In fact, in earlier studies, cannabinoid-receptor
independent effects have been described for both endogenous
and synthetic cannabinoids as well (Johnson et al., 1993; Fan,
1995; Oz et al., 2000). AEA stimulates GTPγS binding in brain
membranes isolated from mice lacking CB1 receptors, and this
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Effects of cannabinoids on nicotinic
acetylcholine receptors
Nicotinic acetylcholine receptors (nAChRs) are cationic
channels belonging to the Cys-loop superfamily of ligandgated ion channels and their opening is controlled by the
endogenous neurotransmitter ACh or exogenous ligands such
as nicotine (Albuquerque et al., 2009; Dineley et al., 2015). They
are homo or hetero-pentameric complexes comprised of α1-10,
β1-6, δ, and γ subunit combinations and mediate fast cholinergic
neurotransmission in both central and peripheral nervous
systems and are expressed in non-neuronal cells as well
(Albuquerque et al., 2009; Zoli et al., 2015). The homomeric
α7-nAChR subtype plays an important role in synaptic plasticity
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(Spivak et al., 2007). CBD, on the other hand, at relatively
high concentration modulates the function of nACh receptors.
In earlier studies, CBD was reported to decrease the amplitudes
of miniature end-plate potentials in frog neuromuscular junction
suggesting an effect on the postsynaptic nACh receptors
(Turkanis and Karler, 1986). Later studies indicated that CBD
inhibits human α7-nACh receptors with an IC50 of 11.3 µM
(Mahgoub et al., 2013; Oz et al., 2014) and suppresses cholineinduced inward currents in rat hippocampal interneurons. CBD
has also been shown to inhibit nicotine-induced [3H]norepinephrine release in rat hippocampal slices (Mahgoub
et al., 2013), and reduce withdrawal symptoms in nicotinedependent rats (Smith et al., 2021) further suggesting an
interaction between CBD and nicotinic receptors. Notably,
Inhibitory effect of CBD was time-dependent with 50%
inhibition occurring in 2.1 min sustained CBD application,
voltage-independent, and non-competitive, i.e., while the EC50
of ACh remained unaltered, maximal ACh responses were
signiﬁcantly decreased (Mahgoub et al., 2013). In line with
these ﬁndings, speciﬁc binding of [125I] α-bungarotoxin
binding was not affected by CBD.
In addition to α7-nicotinic receptor, the α4β2 is the major
nACh receptor subtype in the CNS and has been implicated in
mediating both the positive-reinforcing and cognitive effects
of nicotine (Tapper et al., 2004). The presence of the α4β2nACh receptor subunit appears to be necessary and sufﬁcient
for the development of nicotine-induced tolerance and
sensitization in vivo (Tapper et al., 2004). Using the wholecell patch-clamp technique, Spivak et al., showed that AEA, in
the concentration range of 200 nM to 2 μM, reduced the
maximal amplitudes and increased the desensitization of
acetylcholine-induced currents mediated by human
α4β2 nACh receptors expressed in SH-EP1 cells (Spivak
et al., 2007). The effects of AEA could be neither reversed
by the SR141716A (1 μM) nor replicated by the THC (1 μM).
Interestingly, AEA exerted inhibitory effect when applied
extracellularly but not during intracellular dialysis. Kinetic
analysis of the effect of AEA on α4β2 nACh receptor-mediated
currents demonstrated that the ﬁrst forward rate constant
leading to desensitization increased nearly 30-fold as a linear
function of AEA concentration and the energy levels of the
activated state were raised by AEA (Spivak et al., 2007).
Another study on α4β2 nACh receptors utilized rat
thalamic synaptosomes where the ACh-induced 86Rb+
efﬂuxes carried mainly through native α4β2 nACh
receptors were reversibly inhibited by AEA with an IC50 of
0.9 µM in a noncompetitive manner (Butt et al., 2008).
Inhibitory effect of AEA was not altered by pretreatments
with the CB1 receptor antagonist SR141716A (1 μM), the
CB2 receptor antagonist SR144528 (1 μM), and PTX.
Although α7 and α4β2 receptor subtypes are affected by
AEA, the function of muscle type nicotinic receptor is not
altered by AEA (Oz, 2006). The results of key studies

and
various
disease
pathologies
including
pain,
neuroinﬂammation, and neurodegenerative diseases such as
Alzheimer and Parkinson diseases (Oz et al., 2013; Lorke
et al., 2016; Oz et al., 2016; Borroni and Barrantes, 2021;
Mizrachi et al., 2021; Papke and Horenstein, 2021).
In vivo studies, WIN55,212-2, non-selective cannabinoid
receptor agonist, has been shown to impair memory-related
effects of nicotine in male rats (Robinson et al., 2010) and
mice (Biala and Kruk, 2008). In Xenopus oocytes expressing
α7-nACh receptors, AEA and 2-AG noncompetitively
inhibited α7-nACh receptor-mediated currents with IC 50
values of 229 and 168 nM, respectively (Oz et al., 2003; Oz
et al., 2004b). In line with these ﬁndings, radioligand binding
studies indicated that AEA, at concentration range of 30300 μM, does not alter speciﬁc binding of [ 3 H]nicotine in
human frontal cortex (Lagalwar et al., 1999) and rat thalamic
membranes (Butt et al., 2008), further suggesting a
noncompetitive nature of AEA effect on nACh receptors.
Inhibition of α7-nACh receptor by AEA was not reversed by
either SR 141716A (Rimonabant), speciﬁc CB1 antagonist, or
SR 144528, CB2 antagonist and was not sensitive to pertussis
toxin treatment (Oz et al., 2003). In line with earlier ﬁndings,
arachidonic acid (AA), a fatty acid moiety of AEA
(Vijayaraghavan et al., 1995), but not ethanolamine or
glycerol, inhibited the function of α7-nACh receptors
suggesting that it was the intact endocannabinoid and not
the metabolite AA that altered the function of α7-nACh
receptor. In an in vivo study, Baranowska et al.,
demonstrated that, in the presence of AM2521, a
CB1 antagonist, methanandamide, a metabolically stable
analog of AEA inhibited nicotine-induced tachycardiac
responses mediated by the activation of α7-nACh
receptors on the cardiac postganglionic sympathetic
neurons of urethane anesthetized rats (Baranowska et al.,
2008). In another in vivo study, increased endocannabinoid
levels modulate the somatic signs of nicotine withdrawal by a
mechanism that does not involve CB1 receptors (Merritt
et al., 2008).
Effects of synthetic cannabinoids on the functions of
nACh receptors have been tested in a few studies. In
Xenopus oocytes, WIN55,212-2 was ineffective up to
concentrations of 10 μM, but CP55940 inhibited α7-nACh
receptor with an IC50 value of 2.7 µM (Oz et al., 2004b). On the
other hand, in cultured rat trigeminal ganglion neurons,
patch-clamp studies indicated that native nicotinic receptor
was inhibited by WIN55,212-2 with an IC50 value about 3 µM
in a cannabinoid receptor independent manner (Lu et al.,
2011).
Among the phytocannabinoids tested, THC and cannabinol
up to 10 µM were ineffective (10-20% inhibition) on α7-nACh
receptors expressed in Xenopus oocytes (Oz et al., 2004b;
Mahgoub et al., 2013). Similarly, THC (1 µM) did not affect
the amplitudes of currents through α4β2-nACh receptors
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TABLE 1 Effects of cannabinoids on nicotinic acetylcholine receptors.

Cannabinoid
tested

Effect and conclusion

References

CBD

Decrease of the amplitudes of miniature end-plate potentials in frog neuromuscular junction

Turkanis and Karler,
(1986)

AEA

Inhibition of α7 nACh receptors with IC50 of 229 nM in Xenopus oocytes

Oz et al. (2003)

2-AG

Inhibition of α7 nACh receptors with IC50 of 168 nM in Xenopus oocytes

Oz et al. (2004b)

CP55940

Inhibited α7-nACh receptors with an IC50 value of 2.7 µM in Xenopus oocytes

Oz et al. (2004b)

AEA

In the concentration range of 200 nM to 2 μM, reduced the maximal amplitudes and increased the desensitization of
human α4β2 nACh receptors expressed in SH-EP1 cells

Spivak et al. (2007)

Methanandamide

Methanandamide (3 μmol/kg) produced an AM 251-insensitive inhibition of the nicotine-induced tachycardia

Baranowska et al. (2008)

AEA

Inhibited ACh-induced 86Rb+ efﬂuxes with an IC50 of 0.9 µM in rat thalamic synaptosomes

Butt et al. (2008)

WIN55,212-2

Inhibited native nicotinic receptor with an IC50 value about 3 µM in cultured rat trigeminal ganglion neurons

Lu et al. (2011)

CBD

Inhibits human α7-nACh receptor with an IC50 of 11.3 µM in Xenopus oocytes and rat hippocampal interneurons

Mahgoub et al. (2013)

receptors with an IC50 value of 3.7 μM (Oz et al., 2002a). The
inhibition developed gradually, reaching steady-state within
10–20 min, and it was non-competitive with respect to 5-HT.
In both NGNs and Xenopus oocytes, agents known to modulate
G-protein functions such as PTX treatments and intracellular
applications of GDP-β-S, the nonhydrolyzable analogue of GTP,
as well as applications of agents known to modulate intracellular
cAMP levels did not alter the extent of AEA inhibition of 5-HT3
receptors (Fan, 1995; Oz et al., 2002a). In another study, using
patch clamp technique in excised outside-out patch mode, it was
demonstrated that cannabinoid receptor agonists THC,
WIN55,212-2,
AEA,
JWH-015,
LY320135,
and
CP55,940 inhibited the function of 5-HT3 receptors expressed
in HEK-293 cells with IC50 values of 38, 104, 130, 147, 523, and
648 nM, respectively (Barann et al., 2002). Similarly, inhibition of
5-HT3 receptor mediated currents in rat trigeminal ganglion
neurons by WIN55,212-2 was time and concentrationdependent (IC50 = 0.1 µM), and not reversed by cannabinoid
receptor antagonists (Shi et al., 2012). The inhibition of 5-HT3
receptors by WIN55,212-2 in HEK-293 cells (Barann et al., 2002)
and AEA in Xenopus oocytes (Oz et al., 2002a) was not altered by
SR141716A, and their effects were noncompetitive. The
cannabinoid receptor ligands [3H]-SR141716A and [3H]CP55,940 did not speciﬁcally bind to parental HEK-293 cells.
In competition experiments on membranes of HEK-293 cells
transfected with the 5-HT3 receptor cDNA, WIN55,212-2,
CP55,940, AEA and SR141716A did not affect the binding of
[3H]-GR65630, a speciﬁc ligand for 5-HT3 receptors (Barann
et al., 2002).
Interestingly, potencies of AEA actions on 5-HT3 receptors
differ signiﬁcantly between cell lines such as HEK-293 (Barann
et al., 2002) and Xenopus oocytes (Oz et al., 2002a). The
mechanisms underlying these seemingly discrepant results
were studied in a recent study (Xiong et al., 2008). It was
found that differences in the potencies of AEA inhibition of
5-HT3 receptors between Xenopus laevis oocytes and HEK-

investigating the effects of cannabinoids on nACh receptors
are summarized in Table 1.

Effects of cannabinoids on serotonin type
3 (5-HT3) receptors.
There are seven classes of 5-HT receptors (5-HT1–5-HT7).
5-HT3 receptor is the only ionotropic cation-selective ion
channel which belongs to the superfamily of Cys-loop ligandgated ion channels (Barnes et al., 2009; Lummis, 2012),
remaining 5-HT receptor classes are G-protein-coupled
receptors. To date, there are ﬁve 5-HT3 receptor genes termed
A-E. Only 5-HT3A subunit can assemble as a functional homopentameric channel and 5-HT3A is an obligate participant in all
other 5-HT3 receptor complexes (Lummis, 2012). Activation of
5-HT3 receptors depolarizes neurons and mediates fast,
excitatory synaptic transmission in the central and peripheral
nervous systems. The highest number of 5-HT3 receptor binding
sites occurs in the area postrema and solitary tract nucleus
(Morales and Wang, 2002). In addition, large numbers of 5HT3 receptors are found in the gastrointestinal system where
activation of 5-HT3 receptors are shown to alter gastrointestinal
motility and to regulate the vomiting reﬂex (Sanger and
Andrews, 2006), and they also appear to play a role in
irritable bowel syndrome, visceral pain and inﬂammation
(Faerber et al., 2007; Thompson and Lummis, 2007; Machu,
2011).
Effects of cannabinoids on the functions of 5-HT3 receptors
were ﬁrst demonstrated in nodose ganglion neurons (NGNs) and
Xenopus oocytes (Fan, 1995; Oz et al., 1995). In NGNs, AEA,
WIN55,212-12, CP55,940 and its nonpsychoactive enantiomer
CP56,667 inhibited 5-HT3 receptors with IC50 values of 94 nM,
190 nM, 310 nM and 1.6 μM, respectively (Fan, 1995).
Subsequent studies on 5-HT3 receptors expressed in Xenopus
oocytes showed that AEA directly inhibits the function of 5-HT3
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GR65630 binding on 5-HT3A receptors (Yang et al., 2010a;
Yang et al., 2010b). Importantly, slowing the receptor
desensitization by pharmacological agents such as 5hydroxyindole and nocodazole or mutations such as R427L
markedly decreased the extent of 5-HT3 receptor inhibition by
CBD (Xiong et al., 2011b). Similarly, increasing the expression
level and density of 5-HT3 receptors on the cell membrane
caused a noticeable decrease of receptor desensitization and
the potency of THC on 5-HT3 receptor (Yang et al., 2010b).
Finally, 5-HT3 and CB1 receptors colocalize in hippocampal and
dentate gyrus interneurons (Morales and Bäckman, 2002) and in
other brain regions as well (Morales et al., 2004). Therefore, it is
likely that the actions of cannabinoids including AEA and THC
within the same cell can be mediated by simultaneous dual
actions of cannabinoids on cannabinoid and 5-HT3 receptors.
The results of key studies investigating the effects of
cannabinoids on 5-HT3 receptors are summarized in Table 2.

293 cells were mainly due to different levels of steady-state
receptor density at the cell surface. The magnitude of AEA
inhibition was inversely correlated with the expression level of
receptor protein; i.e., increasing surface receptor expression
decreased the magnitude of AEA inhibition. In line with these
ﬁndings, pretreatment with actinomycin D, an inhibitor of
transcription process, decreased the amplitude of current
activated by maximal 5-HT concentrations and increased the
magnitude of AEA inhibition. AEA accelerated 5-HT3 receptor
desensitization time in a concentration-dependent manner
without signiﬁcantly changing receptor activation and
deactivation time. The desensitization time was correlated
with the AEA-induced inhibition and mean 5-HT current
density. Applications of 5-hydroxyindole and nocodazole, a
microtubule disruptor, signiﬁcantly slowed 5-HT3 receptor
desensitization and reduced the magnitude of AEA inhibition.
Collectively, these ﬁndings suggested that 5-HT3 receptor density
at the steady state regulates receptor desensitization kinetics and
the potency of AEA-induced inhibiting effect on the receptors.
Thus, it appears that the differences in IC50 values for AEA
inhibition of 5-HT3 receptor in Xenopus oocytes (3.7 μM; (Oz
et al., 2002a); and HEK-293 cells (130 nM; (Barann et al., 2002))
are mainly due to the different receptor expression levels among
various cell types.
In vivo studies, WIN55,212-2 and CP55,940 inhibited the
responses mediated by 5-HT3 receptors located on the terminals
of cardiopulmonary afferent C-ﬁbers in anesthetized and
SR141716A pretreated rats (Godlewski et al., 2003). Similarly,
CBD inhibited the reﬂex bradycardia induced by the 5-HT3
receptor
agonist
phenylbiguanide
in
spontaneously
hypertensive rats (Kossakowski et al., 2019). In another in
vivo study, the inhibitory effect of WIN55,212-2 on cocaineinduced locomotor hyperactivity was reported to be mediated by
the inhibition of 5-HT3 receptors (Przegaliński et al., 2005). In a
recent study, mice deﬁcient in CB1 and CB2 receptors were
treated with THC and AEA, in the presence of the 5-HT3
antagonist ondansetron (Rácz et al., 2008). AEA induced
analgesia, but not catalepsy, is completely blocked by
ondansetron, suggesting that 5-HT3 receptors are involved in
cannabinoid-induced analgesia in a manner independent of
known cannabinoid receptors (Rácz et al., 2008).
Both THC and CBD were shown to directly interact with 5HT3 receptors expressed in HEK-293 cells (Barann et al., 2002;
Xiong et al., 2011b), Xenopus oocytes, and NGNs (Yang et al.,
2010a; Yang et al., 2010b; Xiong et al., 2011b). Depending on the
expression levels of the receptor, THC and CBD inhibited human
5-HT3A receptors with respective IC50 values of 1.2 µM and
0.6 µM in Xenopus oocytes (Yang et al., 2010a; Yang et al., 2010b)
and 119 nM and 329 nM in HEK-293 cells (Xiong et al., 2011b).
Inhibition by these cannabinoids was voltage-independent, noncompetitive, and increased with sustained application
(preincubation) time. In line with non-competitive nature of
their effect, THC and CBD did not alter the speciﬁc [3H]
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Effects of cannabinoids on ionotropic
glutamate receptors
Glutamate mediates most excitatory neurotransmission in
the mammalian central nervous system through activation of
metabotropic, G protein–coupled glutamate receptors, and
ionotropic glutamate receptors, which are cation-selective
ligand-gated ion channels. Ionotropic glutamate receptors are
divided into different functional classes, namely α-amino-3hydroxy-5-methyl-4-isoxazolepropionic
acid
(AMPA)
receptors, kainate receptors, N-methyl-D-aspartate (NMDA)
receptors, and GluD (Δ) receptors (Hansen et al., 2021). In
vivo studies, synthetic cannabinoid HU211 protected against
tremorogenic, convulsive, and lethal effects of NMDA in mice
and acted as a functional antagonist in radioligand binding
studies (Feigenbaum et al., 1989). Similarly, NMDA-induced
toxicity was reversed by THC, but not WIN55,212-2 in
SR141716A insensitive manner in AF5 cells (Chen et al.,
2005). AEA (1-10 µM), but not THC, potentiated NR1/NR2A
NMDA receptor-mediated currents in Xenopus oocytes and
increased NMDA-induced intracellular Ca2+ transients in the
presence of SR141716A in rat cortical, cerebellar, and
hippocampal slices (Hampson et al., 1998). 2-AG (5 µM)
enhanced NMDA-evoked currents in a CB1 and
TRPV1 receptor-independent manner through activation of
PKC/Src signaling pathway (Yang et al., 2014). In studies of
blood pressure control in rats, it was found that AEA produces a
pressor effect in the presence of SR141716A and this increase in
pressure was partially reduced by the NMDA receptor antagonist
MK-801, suggesting a possible direct interaction between NMDA
receptors and AEA with relevance to central control of blood
pressure (Malinowska et al., 2010).
CBD inhibited AMPA-glutamate receptor-mediated evoked
excitatory postsynaptic currents and suppressed the frequency
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TABLE 2 Effects of cannabinoids on 5-HT3 receptors.

Cannabinoid tested

Effect and conclusion

References

AEA

Inhibited 5-HT3 receptors with IC50 value of 94 nM in nodose ganglion neurons

Fan, (1995)

WIN55,212-12 and CP55,940

WIN55,212-12 and CP55,940 inhibited 5-HT3 receptors with IC50 values of 310 nM and 1.6 μM,
respectively in nodose ganglion neurons

Fan, (1995)

AEA

Inhibits 5-HT3 receptors with an IC50 value of 3.7 μM in Xenopus oocytes

Oz et al. (2002a)

THC

Inhibits 5-HT3 receptors with an IC50 value of 38 nM in HEK-293 cells

Barann et al. (2002)

AEA

Inhibits 5-HT3 receptors with an IC50 value of 130 nM in HEK-293 cells

Barann et al. (2002)

WIN55,212-2, JWH-015, LY320135, and
CP55940

WIN55,212-2, JWH-015, LY320135, and CP55940 inhibit 5-HT3 receptors with IC50 values of 104,
147, 523, and 648 nM, respectively in HEK-293 cells

Barann et al. (2002)

WIN55,212-2 and CP55,940

They inhibited the cardiovascular responses mediated by 5-HT3 receptors in anesthetized and
SR141716A pretreated rats

Godlewski et al. (2003)

AEA

AEA induced analgesia is completely blocked by ondansetron in CB1 and CB2 knock-out mice

Rácz et al. (2008)

CBD

Inhibited human 5-HT3A receptors with an IC50 of 0.6 µM in Xenopus oocytes

Yang et al. (2010a)

THC

Inhibited human 5-HT3A receptors with an IC50 of 1.2 µM in Xenopus oocytes

Yang et al. (2010b)

CBD

Inhibited human 5-HT3A receptors with an IC50 of 329 nM in HEK-293 cells

Xiong et al. (2011b)

THC

Inhibited human 5-HT3A receptors with an IC50 of 119 nM in HEK-293 cells

Xiong et al. (2011b)

WIN55,212-2

Inhibition of 5-HT3 receptor with an IC50 of 0.1 µM in rat trigeminal ganglion

Shi et al. (2012)

CBD

Inhibited the reﬂex bradycardia induced by the 5-HT3 receptor agonist phenylbiguanide in
spontaneously hypertensive rats

Kossakowski et al.
(2019)

hyperekplexia, temporal lobe epilepsy, autism, breathing
disorders, and chronic inﬂammatory pain (Lynch et al., 2017).
In earlier studies, co-application of glycine with AEA or 2AG (0.2-2 µM), independent of activation of CB1 and
TRPV1 receptors, markedly inhibited peak amplitudes and
accelerated onset and desensitization of high (100 µM)
glycine-activated currents in pyramidal neurons isolated from
the hippocampus of neonatal rats (Lozovaya et al., 2005). In
contrast to endocannabinoids, WIN55,212-2 (1 µM) did not
signiﬁcantly affect peak amplitudes but signiﬁcantly
accelerated the desensitization as well as onset of currents
activated by high concentrations (100 µM) of glycine
(Lozovaya et al., 2005; Yatsenko and Lozovaya, 2007) but
potentiated the amplitudes of currents at low (40 µM) glycine
concentrations (Iatsenko et al., 2007). Other cannabinoids such
as HU-210 (Yang et al., 2008; Demir et al., 2009; Xiong et al.,
2012b) and ajulemic acid (Ahrens et al., 2009b) also act as
positive allosteric modulators of α1 glycine receptors.
Co-application of AEA (1-10 µM) with low (EC10; 3-10 µM)
concentrations of glycine potentiated the glycine-induced
currents mediated by homomeric α1, α2, and α3 glycine
receptors expressed in HEK-293 cells (Yang et al., 2008;
Yévenes and Zeilhofer, 2011), Xenopus oocytes, and CNS
neurons (Hejazi et al., 2006) in a CB receptor-independent
manner. AEA-induced potentiation of these three glycine
receptor subtypes was reduced by mutating a conserved
intracellular lysine residue (K385A), whereas potentiation of
α1 receptor induced by N-arachidonoyl-glycine was reduced
by mutating loop 2 (A52), transmembrane 2 (G254) or
intracellular (K385) amino acids (Yévenes and Zeilhofer,

and amplitudes of miniature excitatory postsynaptic currents in
mice hippocampal neurons (Yu et al., 2020). Furthermore, in
HEK-293 cells, CBD was shown to inhibit recombinant
GluA1 currents with IC50 of 22.5 µM and facilitate the
deactivations of GluA1 and GluA2 receptors and slow the
recovery of GluA1 receptor from desensitization (Yu et al.,
2020). In line with these ﬁndings, CBD alleviate behavioral
hyperactivity and hippocampal c-Fos expression in Gria1−/−
mice which is a model sensitive to drugs that downregulate
glutamatergic transmission such AMPA antagonists (Aitta-Aho
et al., 2019). AEA, at high concentrations, inhibits homomeric
GluR1 and GluR3 subunit-mediated currents with IC50 of
161 µM and 143 μM, respectively (Akinshola et al., 1999).
AEA inhibited heteromeric GluR1/3 and GluR2/3 receptor
subunits with similar IC50 value of 148 µM and 241 μM,
respectively.

Effects of cannabinoids on glycine
receptors
Glycine receptors are inhibitory, anion-selective Cys-loop
ligand-gated ion channels that mediate fast inhibitory
neurotransmission in the spinal cord, brainstem and retina
(Lynch, 2009). There are four known glycine receptor α
subunits (α1–α4) and a single β subunit in vertebrates.
Functional receptors assemble as homo-pentamers of α
subunits, or as hetero-pentamers of α and β subunits (Burgos
et al., 2016). Malfunctions of glycine receptors have been
associated with a range of neurological disorders including
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and direct activation of glycine receptor by CBD (Foadi et al.,
2010). However, THC-induced potentiation was not affected
when the S267Q mutant α1 glycine receptors were expressed
in Xenopus oocytes (Hejazi et al., 2006). In subsequent studies, it
was shown that continuous application, but not co-application,
of THC (1 µM) for about 5 min caused a gradually developing
marked potentiation (up to 1,200%) of glycine activated currents
in HEK-293 cells expressing α1, α3, and α1β1, but not α2,
subunits of glycine receptor (Xiong et al., 2011a). Notably,
S296 residue of the α1 and the S307 of the α3 subunits have
been shown to be critical for the potentiation of glycine receptors
by continuous, but not simultaneous, THC application (Xiong
et al., 2011a; Xiong et al., 2012b). Conversely, substitution of the
corresponding residue, Ala303 of the α2 subunit with a serine
converted the α2 subunit from a low to high THC sensitivity.
Similar to THC, the CBD, dehydroxyl-CBD, and dehydroxylTHC have also been shown to potentiate glycine-activated
currents of α1 and α3 subunits (Xiong et al., 2011a; Xiong
et al., 2012a; Xiong et al., 2012b). Further studies indicated
that CBD and dehydroxyl-CBD suppress persistent
inﬂammatory and neuropathic pain by potentiating α3 glycine
receptor-mediated currents in HEK-293 cells and cultured spinal
neurons and the CBD suppression of neuropathic pain was
reversed in α3-knock-out mouse (Xiong et al., 2012a). In
subsequent studies, dehydroxyl-CBD was reported to suppress
inﬂammatory pain and potentiate α1-glycine receptors by
interacting with S296 amino acid residue. Accordingly,
analgesic effect of dehydroxyl-CBD was reversed in the
transgenic mice carrying S296A mutation, which also blocks
DH-CBD-induced potentiation of glycine-activated currents in
neurons of the spinal cord dorsal horn in mutant mouse (Lu et al.,
2018). In another study, dehydroxyl-CBD rescued functional
deﬁciency of glycine receptor and exaggerated acoustic and
tactile startle responses in mice bearing point mutations in
α1 glycine receptors that are responsible for a hereditary
startle-hyperekplexia disease (Xiong et al., 2014). Recently,
cannabinoids such as THC and CBD were reported to rescue
cocaine-induced seizures by restoring brain glycine receptor
dysfunction in a cannabinoid-receptor independent manner
(Zou et al., 2020b). The results of key studies investigating the
effects of cannabinoids on glycine receptors are summarized in
Table 3.

2011). In another study, AEA (1-30 µM) substantially increased
the amplitude of glycine-activated currents in cultured rat spinal
neurons (Xiong et al., 2012b). The effect reached a steady-state
within 5 min continuous AEA application and markedly
diminished by increasing glycine concentrations. In HEK293 cells, AEA potentiation of homomeric α1 and
α3 receptors was signiﬁcantly higher than α2 glycine
receptors. While S296A and S307A mutations in
transmembrane three domains of α1 and α3 receptors
markedly decreased the potentiation by sustained
(continuous), but not simultaneous co-application of AEA,
A303S mutation increased the potentiation of α2 glycine
receptors by AEA. The S296A mutation also decreased the
extent of α1 receptor potentiation by other cannabinoids such
as CBD, THC, and HU-210 (Xiong et al., 2012b). Importantly,
the authors of this study also showed in control studies that these
mutations have no signiﬁcant effect on the pharmacological
properties of glycine receptors. Furthermore, removal of
hydroxy or oxygen groups in AEA and THC signiﬁcantly
reduced the potentiating effects of these compounds on
α1 glycine receptor suggesting that these groups are important
for their effects on glycine receptor. In outside-out patches in
CHO cells expressing human α1 glycine receptor, continuous
application of 2-AG (1 µM) inhibited the peak amplitudes,
decreased the rise time, accelerated the desensitization rate,
and slowed down the deactivation of the receptor activated by
glycine at the level of EC50 (40-70 µM). Notably, inhibitory effect
of AEA was signiﬁcantly less at low (20 µM) and high (1 mM)
concentrations of glycine (Lozovaya et al., 2011). In further
studies mimicking synaptic stimulation in outside-out patches
from CHO cells by applying high concentration of glycine
(1 mM) for 2 ms duration at 10 Hz frequency, application of
2-AG markedly reduced the amplitudes of glycine-induced
currents. Similarly, in hypoglossal motoneurons of
CB1 knock-out mice, 2-AG abolished the facilitation of
synaptic glycinergic currents induced by repetitive (10-20 Hz)
stimulations indicating that endocannabinoids can modulate
synaptic transmission under physiological conditions in a
cannabinoid-receptor-independent manner (Lozovaya et al.,
2011).
CBD and THC have been shown to potentiate glycine
receptor-mediated currents in a cannabinoid receptorindependent manner in Xenopus oocytes expressing
homomeric α1 and heteromeric α1β glycine receptors, and in
acutely isolated CNS neurons (Hejazi et al., 2006; Xiong et al.,
2011a; Wells et al., 2015). CBD was reported to act as positive
allosteric modulator of α1 and α1β1 glycine receptors expressed
in HEK-293 cells with EC50 values of 12.3 µM and 18.1 µM,
respectively (Ahrens et al., 2009a). Notably, at higher
concentration range, CBD directly acts as agonist of α1 and
α1β1 glycine receptors with respective EC50 values of 132.4 µM
and 144.3 µM. The mutation of the α1 subunit transmembrane
two serine 267) residue to isoleucine abolished both co-activation
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Effects of cannabinoids on GABAA
receptors
γ-Aminobutyric acid (GABA), the major inhibitory
neurotransmitter in the brain, exerts its action via ionotropic
GABAA and metabotropic GABAB receptors. GABAA receptors,
like glycine receptors, are anion-selective Cys-loop ligand-gated
ion channels activated by GABA and the selective agonist
muscimol, blocked by bicuculline and picrotoxin, and
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TABLE 3 Effects of cannabinoids on glycine receptors.

Cannabinoid
tested

Effect and conclusion

References

AEA

Inhibition of peak amplitudes and increasing desensitization of glycine induced currents by AEA (0.2-2 µM) in
pyramidal neurons of neonatal rat hippocampus

Lozovaya et al. (2005)

2-AG

Inhibition of peak amplitudes and increasing desensitization of glycine induced currents by 2-AG (0.2-2 µM) in
pyramidal neurons of neonatal rat hippocampus

Lozovaya et al. (2005)

AEA

Potentiation of glycine (low concentrations)-induced currents mediated by α1 and α1β1 receptors with EC50 of
319 and, 318 nM, respectively, in Xenopus oocytes and also in ventral tegmental area neurons

Hejazi et al. (2006)

THC

Potentiation of glycine (low concentrations)-induced currents mediated by α1 and α1β1 receptors with EC50 of
86 and 71 nM, respectively, in Xenopus oocytes and also in ventral tegmental area neurons

Hejazi et al. (2006)

WIN55,212-2

Potentiation of glycine (low concentrations) currents in pyramidal neurons of rat hippocampus

Iatsenko et al. (2007)

AEA

Potentiated the glycine (low concentration)-induced currents mediated by homomeric α1, α2, and α3 glycine
receptors expressed in HEK-293 cells

Yang et al. (2008)
Yang et al. (2008)

HU-210

Potentiation of α1 and α1β but inhibition of α2 subunit currents in HEK-293 cells

WIN55,212-2

Inhibition of α2 and α3 subunit currents in HEK-293 cells

Yang et al. (2008)

HU-210

Potentiation of α1subunit currents with an EC50 of 5.1 µM in HEK-293 cells

Demir et al. (2009)

CBD

Potentiated α1 and α1β1 glycine receptors expressed in HEK-293 cells with EC50 values of 12.3 and 18.1 µM,
respectively

Ahrens et al. (2009a)

Ajulemic acid

Potentiation of α1 and α1β subunit glycine receptors in HEK-293 cells with EC50 values of 9.7 and 12.4 μM,
respectively

Ahrens et al. (2009b)

2-AG

Inhibited α1 subunit glycine receptors expressed in CHO cells and in hypoglossal motoneurons of CB1 knock-out
mice

Lozovaya et al. (2011)

N-arachidonoyl-glycine

Potentiated the glycine (low concentration)-induced currents mediated by α1, but inhibited α2, and α3 glycine
receptors expressed in HEK-293 cells

Yévenes and Zeilhofer,
(2011)

AEA

Potentiated the glycine (low concentration)-induced currents mediated by homomeric α1, α2, and α3 glycine
receptors expressed in HEK-293 cells

Yévenes and Zeilhofer,
(2011)

THC

Potentiation of glycine activated currents in HEK-293 cells expressing α1, α3, and α1β1, but not α2, subunits of
glycine receptor

Xiong et al. (2011a)

CBD

Potentiate glycine-activated currents of α3 subunits expressed in HEK-293 cells and dorsal horn neurons in rat
spinal cord slices

Xiong et al. (2012a)

AEA

Potentiated the glycine-activated currents mediated by homomeric α1, α2, and α3 glycine receptors expressed in
HEK-293 cells and in cultured rat spinal neurons

Xiong et al. (2012b)

CBD and THC

Potentiated the low glycine-activated currents mediated by homomeric α1 glycine receptors expressed in HEK-293
cells

Xiong et al. (2012b)

ﬂunitrazepam to mouse brain in vivo, potentiated the
anticonvulsant effects of diazepam against pentylenetetrazol,
and elicited analgesic effects that correlated with the potency
of their facilitatory effects on [3H]-ﬂunitrazepam binding (Koe
and Weissman, 1981; Koe et al., 1985) suggesting that
cannabinoids can interact with GABAA receptors.
Furthermore, benzodiazepines such as diazepam partially
substitutes for THC in drug discrimination studies (Mokler
et al., 1986) and this effect was not antagonized by
CB1 receptor antagonist SR141716 (Wiley and Martin, 1999).
More recently, effects of cannabinoids on the functional
properties of GABAA receptors has been shown in
heterologous expression systems and native neurons. In
Xenopus oocytes expressing α1-6β2γ2 subunits of GABAA
receptors, 2-AG potentiated currents activated low GABA
concentrations (EC5 = 0.1-10 µM) with EC50 values ranging
from 1.5 µM to 15.7 µM and signiﬁcantly shifted GABA
concentration-response curves to the left (Sigel et al., 2011;

modulated by benzodiazepines, barbiturates, and some other
classes of depressants (Olsen and Sieghart, 2008; Sigel and
Steinmann, 2012). Consequently, drugs modulating the
activity of GABAA receptors play a critical role in the
treatment of neuropsychiatric disorders such as epilepsy,
anxiety, and insomnia, as well as in anesthesia (Olsen and
Sieghart, 2008; Olsen, 2018; Ghit et al., 2021). A total of
19 GABAA receptor subunit genes have been identiﬁed in
humans that code for six α1-6, three β1-3, three γ1-3, three
ρ1-3, and one each of the δ, ε, π, and θ (Sigel and Steinmann,
2012). They are usually constructed with two copies of an α
subunit, two copies of a β subunit, and one copy of either a γ
subunit, or another such as Δ, to form several combinations of
hetero-pentameric GABAA receptor subtypes (Sigel and
Steinmann, 2012; Olsen, 2018).
In early radioligand binding studies, synthetic cannabinoids
such as levonantradol, nabilone, CP-47,497 (-)-CP-55,940 and
(-)-CP-55,244 enhanced the speciﬁc binding of [3H]-
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Xenopus oocytes expressing α1β2γ2 subunit combination of
GABAA receptors (Anderson et al., 2019). In addition to
CBD, THC (3 µM) has also been shown to potentiate (about
100%) α1β2γ2 GABAA receptors activated by low concentrations
(EC2) of GABA (Yao et al., 2020b). In another study, the rundown of GABA (500 µM) activated currents in Xenopus oocytes
transplanted with hippocampal membranes from epileptic
patients was signiﬁcantly reversed by 2 h pretreatment with
50 nM cannabidivarin, a non-psychoactive homolog of CBD
(Morano et al., 2016). In a recent study, cannabigerolic acid,
the biosynthetic precursor to both THC and CBD, has been
shown to increase GABA (15 µM) activated currents to 271% of
controls with EC50 of 910 nM in Xenopus oocytes expressing
human α1β2γ2 GABAA receptors (Anderson et al., 2021). In
addition, this study showed that cannabigerolic acid potentiated
the anticonvulsant effects of clobazam against hyperthermiainduced and spontaneous seizures and displayed anticonvulsant
effects
in
maximal
electroshock
model.
Recently,
dehydroxylcannabidiol,
a
synthetic
nonpsychoactive
cannabinoid, has been shown to restore the GABA- and
glycine-activated currents in HEK-293 cells co-expressing a
major GABAA receptor isoform (α1β2γ2) and α1 glycine
receptor carrying a human hyperekplexia-associated mutation
(R271Q), suggesting that cannabinoids can be potentially
valuable candidate drugs to manage hyperekplexia (Zou et al.,
2020a). Collectively, these results indicate that both CBD and
THC act as positive allosteric modulators of glycine and GABAA
receptors, especially at low agonist concentrations and subunit
speciﬁc manner. The results of key studies investigating the
effects of cannabinoids on GABAA receptors are summarized
in Table 4.

Bakas et al., 2017). 2-AG also potentiated extrasynaptic δ-subunit
containing α4β2δ GABAA receptors (Bakas et al., 2017).
Potentiation of GABA-evoked currents by 2-AG was
signiﬁcantly greater at GABAA-receptors containing a β2 or
β3 subunit and markedly reduced by α2β2(V436T)γ2L and
α2β2(VF439L)γ2L mutations in transmembrane domain 4
(Sigel et al., 2011). Subsequent studies have identiﬁed four
amino acid residues in transmembrane domain 4 of the
β2 subunit, β2W428, β2S429, β2F432, and β2V443 and in
transmembrane domain 3, β2V302, in addition to the residues
previously described, β2M294 and β2L301 (Baur et al., 2013b). In
addition to cannabinoid receptor agonists, antagonists of these
receptors have also been shown to directly modulate GABAA
receptors. SR141716 (rimonabant) and AM251 allosterically
potentiated low (0.5 µM) GABA activated currents to maximal
potentiations of 3,381% and 881% of controls with EC50 values of
7.3 µM and 0.4 µM, respectively in Xenopus oocytes expressing
α1β2γ2 GABAA receptor (Baur et al., 2012). Another study on
dissociated basolateral amygdala neurons, reported that AM251
(1 µM) caused 30% reduction on the peak amplitudes of GABA
(5 µM)-activated currents (Zhu and Lovinger, 2005).
In HEK-293 cells expressing α1β2γ2 and α2β2γ2 subunit
combinations of GABA receptors and acutely isolated
hippocampal pyramidal neurons from rat brain, 2-AG, AEA,
and CP55,940, at 1 µM concentrations, signiﬁcantly inhibited
peak amplitudes and increased desensitization of currents
activated by high (1 mM) concentration of GABA (Golovko
et al., 2015). In CB1 knock-out mice or in rat somatosensory
cortex pyramidal neurons pretreated with 5 μM SR141716A,
synthetic cannabinoids CP55,940 (1 µM) and WIN55,212-2
(5 µM) gradually reduced the amplitudes of evoked
GABAergic postsynaptic currents.
CBD has been shown to act as a positive allosteric modulator,
with EC50 values ranging from 0.9 µM to 16.1 µM and
magnitudes of potentiation in the range of 72%–332% at
αβγ2 receptor combinations, with higher level of potentiation
on α2 containing subtype combination (Bakas et al., 2017). The
greatest levels of enhancements by CBD were reported as 332%
on α2β2γ2L and 752% on α4β2δ subunit combinations and the
classical benzodiazepine binding site located at α-γ2L interface
does not seem to be involved in CBD interaction with GABAA
receptors. Furthermore, CBD potentiation of α2β2γ2L was
signiﬁcantly decreased by α2β2(V436T)γ2L mutation on
transmembrane domain 4. Notably, CBD potentiation of
GABAA receptors was signiﬁcantly decreased with increasing
GABA concentrations, resulting in decreased GABA EC50 values
with no apparent change in the Emax. In a recent study, CBD
(2 µM) induced 30-50% potentiation of GABA (1-10 µM)
activated currents in Xenopus oocytes expressing human
α1β2γ2, α1β2, and α2β2γ2, α2β2 subunit combinations of
GABAA receptors (Ruffolo et al., 2018). In another
investigation, CBD (10 µM) caused 106% potentiation, with
EC50 of 2.4 µM, of GABA (15 µM)-activated currents in
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Discussion
Cannabinoids are highly lipophilic compounds with a LogP
(octanol–water partition coefﬁcient) values ranging between
4 and 9. Thus, it is likely that these lipophilic molecules ﬁrst
dissolve into the lipid membrane and then diffuse into a nonannular lipid space to allosterically inhibit the ion channels.
Consistent with this idea, the effect of cannabinoids on ion
channels usually reaches a maximal level within several
minutes (5-10 min) of sustained applications.
Notably, functional properties of ligand-gated ion channels
have been shown to be affected by the activation of second
messenger pathways (Siara et al., 1990; Hoffman et al., 1994;
Zhang et al., 1995; Nishizaki and Sumikawa, 1998). However,
agents modulating cAMP and protein kinase C pathways and
chelation of intracellular Ca2+ do not alter the effects of
endocannabinoids on LGICs (Oz et al., 2002a; Oz et al.,
2003). Beside cannabinoids, actions of several lipophilic
modulators, such as capsaicin (Lundbaek et al., 2005; Alzaabi
et al., 2019; Nebrisi et al., 2020), endocannabinoids (Oz et al.,
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TABLE 4 Effects of cannabinoids on GABAA receptors.

Cannabinoid
tested

Effect and conclusion

References

AM251

30% reduction on the peak amplitudes of GABA (5 µM)-activated currents by 1 µM AM251 in isolated basolateral
amygdala neurons

Zhu and Lovinger,
(2005)

2-AG

Potentiated α1-6β2γ2 subunits of GABAA receptors activated by low GABA (0.1-10 µM) with EC50 values ranging
from 1.5 µM to 15.7 µM in Xenopus oocytes

Sigel et al. (2011)

SR141716 and AM251

Potentiated low (0.5 µM) GABA activated currents with EC50 values of 7.3 and 0.4 µM, for SR141716 and AM251,
respectively in Xenopus oocytes expressing α1β2γ2 GABAA receptor

Baur et al. (2012)

AEA and 2-AG

Inhibited peak amplitudes and increased desensitization of currents activated by high (1 mM) GABA in HEK-293
cells expressing α1β2γ2 and α2β2γ2 subunits of GABAA receptors and acutely isolated rat hippocampal pyramidal
neurons

Golovko et al. (2015)

CP55,940

Inhibited peak amplitudes and increased desensitization of currents activated by high (1 mM) GABA in HEK-293
cells expressing α1β2γ2 and α2β2γ2 subunits of GABAA receptors and acutely isolated rat hippocampal pyramidal
neurons

Golovko et al. (2015)

2-AG

Potentiated α1-6β2γ2 and extrasynaptic δ-subunit containing α4β2δ GABAA receptors at low GABA concentrations
in Xenopus oocytes

Bakas et al. (2017)

CBD

Potentiated α1-6β2γ2 and extrasynaptic δ-subunit containing α4β2δ GABAA receptors at low GABA concentrations
with EC50 values ranging from 0.9 µM to 16.1 µM in Xenopus oocytes

Bakas et al. (2017)

CBD

Potentiation of GABA (1-10 µM) activated currents in Xenopus oocytes expressing human α1β2γ2, α1β2, and α2β2γ2,
α2β2 subunit combinations of GABAA receptors

Ruffolo et al. (2018)

CBD

Potentiation, with EC50 of 2.4 µM, of GABA (15 µM)-activated currents in Xenopus oocytes expressing
α1β2γ2 subunit combination of GABAA receptors

Anderson et al. (2019)

THC

Potentiate α1β2γ2 GABAA receptors activated by low concentrations of GABA

Yao et al. (2020b)

Cannabigerolic acid

Potentiate GABA activated currents with EC50 of 910 nM in Xenopus oocytes expressing human α1β2γ2 GABAA
receptors

Anderson et al. (2021)

2018). In favor of speciﬁc binding site on ion channels,
WIN55,212-3, cannabinoid receptor-inactive enantiomer of
WIN55,212-2, did not affect the 5-HT3 receptor-mediated
currents (Barann et al., 2002), conﬁrming earlier results with
CP56667 on nodose ganglion neurons (Fan, 1995) and indicating
that although their effects are not mediated by the activation of
cannabinoid receptors, these synthetic cannabinoids inhibit 5HT3 receptors in an enantiomer-speciﬁc manner possibly
through a hydrophobic bindings site within the bilayer
membrane. As a result of these mechanisms, it is likely that
cannabinoids affect the energy requirements for gating-related
conformational changes and allosterically modulate the
functional properties of ion channels (Spivak et al., 2007).
Interaction between allosteric modulators and cannabinoids
has also been investigated in a few studies. While, general
anesthetics (Jackson et al., 2008), ethanol (Oz et al., 2005),
and neurosteroids (Sigel et al., 2011) exert additive effects
with endocannabinoids, fatty acid amides such as
docosatetraenylethanolamide (Baur et al., 2013a; Baur et al.,
2013b) antagonize the positive allosteric effects of
endocannabinoids suggesting distinct binding sites for these
modulators. In conclusion, both membrane disturbing effects
and a hydrophobic bindings site(s) within the transmembrane
regions of the LGIC can mediate the modulatory actions of
cannabinoids on these channels (Figure 1).
Cannabinoids also appear to interact with other membrane
lipids such as cholesterol to exert their effects (Martin et al.,

2004a; Spivak et al., 2007), general anesthetics (Zhang et al., 1997;
Jackson et al., 2008), and steroids (Oz et al., 2002b) on various ion
channels require 5-10 min continuous application times to reach
their maxima, suggesting that their binding site(s) is/are located
inside the lipid membrane and require a relatively slow
equilibrium time to exert their effect. From this aspect, it
appears that alone or the combination of two mechanisms can
describe the lipophilic actions of cannabinoids (Oz, 2006; Oz
et al., 2014; Ghovanloo and Ruben, 2021). First, cannabinoids,
like other lipophilic molecules, partition into the lipid bilayer and
alter the biophysical properties of the membrane by reducing
membrane electrical resistance (Bach et al., 1976), increasing
membrane ﬂuidity (Hillard et al., 1985; Mavromoustakos et al.,
2001; Dainese et al., 2012), changing membrane order (Bloom
et al., 1997), increasing membrane stiffness (Ghovanloo et al.,
2021; Ghovanloo and Ruben, 2021), increasing membrane
elasticity (Medeiros et al., 2017; James et al., 2022), and
changing physicochemical and structural properties of bilayer
membranes (Makriyannis et al., 1990; Yang et al., 1992; Ambrosi
et al., 2005; Tiburu et al., 2007; Tian et al., 2011). Secondly,
cannabinoids can bind directly to transmembrane domains of
ion channels embedded in the cell membrane (Xiong et al.,
2011a; Xiong et al., 2012b; Lu et al., 2018; Ghovanloo et al.,
2021). In fact, residue S296 in transmembrane domain of
α1 glycine receptor has been reported to interact with
cannabinoids and mediate their potentiating effect on these
receptors (Xiong et al., 2011a; Xiong et al., 2012b; Lu et al.,
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FIGURE 1
Cannabinoids interact with the lipid membrane and inﬂuence the functional properties of ion channels and other integral membrane proteins.
Cannabinoids enter the lipid membrane and binds to cannabinoid receptors through lipid membrane (Reggio and Traore, 2000; Barnett-Norris et al.,
2005; Makriyannis et al., 2005). In addition, cannabinoids directly affect channel function by changing the biophysical properties of the lipid
membrane or binding to a hydrophobic binding site(s) located on the transmembrane regions of ligand-gated ion channels (represented with
large dashed red arrow). Cannabinoids, like other lipophilic molecules, partition into the lipid bilayer and alter the biophysical properties of the
membrane by reducing membrane electrical resistance, increasing membrane ﬂuidity, changing membrane order, increasing membrane stiffness,
increasing membrane elasticity, and changing physicochemical and structural properties of bilayer membranes (represented with thinner diagonal
red arrows). Secondly, cannabinoids can bind directly to transmembrane domains of ion channels embedded in the cell membrane (see discussion).

cannabichromene, and the sesquiterpene (E)-β-caryophyllene
have also been shown to bind and fully or partially activate
cannabinoid receptors (Husni et al., 2014; Pertwee and Cascio,
2014; Zagzoog et al., 2020). Notably, majority of
phytocannabinoids that do not interact with cannabinoids
receptors and several phenolic terpenes found in the cannabis
plant also act as allosteric modulators of various ion channels
including several members of LGICs (Nurulain et al., 2015; Oz
et al., 2015; Hoffmann et al., 2016; Lozon et al., 2016; Al Kury
et al., 2018), suggesting that these compounds can also potentially
contribute to allosteric effects of cannabis through cannabinoid
receptor-independent mechanisms. Importantly, in addition
to LGICs, cannabinoids act through cannabinoidindependent mechanisms to modulate the functions of
TRP channels (Muller et al., 2018; Storozhuk and Zholos,
2018), PPARs (Iannotti and Vitale, 2021; Lago-Fernandez
et al., 2021), 5-HT1A receptors (Russo et al., 2005; Rodrigues da
Silva et al., 2020; Yano et al., 2020), and other receptors (Ibeas Bih
et al., 2015; Morales et al., 2017; Turner et al., 2017).
Lipophilic features of cannabinoids markedly affect their
pharmacokinetic properties as well. In biochemical studies, tissue
AEA and 2-AG concentrations range between 10-214 pmol/g
(9 nM–195 nM) and 1-21 nmol/g (1 µM–19 µM), respectively

2021). The presence of cholesterol in phosphatidylcholine
bilayers increased THC- phosphatidylcholine complex
formation and high cholesterol concentrations were proposed
to enhance THC activity in the bilayer membrane (Bruggemann
and Melchior, 1983). In another study, cholesterol was shown to
stimulate both the insertion of AEA into bilayer membranes, and
its transport across these membranes (Di Pasquale et al., 2009).
Interestingly, cholesterol seems to provide structural support to
CBD binding site on the glycine receptors. Removal of membrane
cholesterol by cyclodextrin (Yao et al., 2020b) or anti-cholesterol
drug such as simvastatin (Yao et al., 2020a) markedly reversed
THC or dehydroxyl-CBD potentiation of α1 and α3 glycine
receptors by interacting with the S296 residue suggesting that
cholesterol directly interact with these cannabinoids on this
binding pocket. Another recent study indicates that
membrane orientation of CBD and its effect on water
permeability were signiﬁcantly altered in the presence of
cholesterol suggesting an interaction between CBD and
cholesterol in lipid membranes (Perez et al., 2022).
Among more than 120 phytocannabinoids found in
cannabis, to date, beside THC, some other cannabinoids such
as cannabinol, (−)-trans-Δ8-tetrahydrocannabinol, (−)-trans-Δ9tetrahydrocannabivarin,
cannabidivarin,
cannabigerol,
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cannabinoids exert their effects by modulating activities of ion
channels; transporters; enzymes, and other G-proteincoupled receptors in a cannabinoid receptor-independent
manner. Among these diverse array of cellular
macromolecules, ligand-gated ion channels constitute an
important
target
that
can
effectively
modulate
neurotransmission in both central and peripheral nervous
system.

(Buczynski and Parsons, 2010). However, tissue endocannabinoid
concentrations display signiﬁcant spatiotemporal differences among
brain regions and within the cell as well. Presumably, de novo
synthesized endocannabinoids are preferentially incorporated into
lipid membranes and give rise to spatially localized signaling within
the cell. Similarly, phytocannabinoids, due to their high lipophilicity,
are expected to attain membrane concentrations that are
considerably higher than blood levels (Deiana et al., 2012). In an
earlier study, it has been shown that perfusion of isolated rat hearts
with buffer containing [3H]-CBD results in strong accumulation of
radioactivity in the tissue (Smiley et al., 1976). Recently, chronic
(28 days) administration of CBD (230 mg/kg) was shown to reach
CBD concentrations of 2.7 µM and 3.3 µM in muscle and liver
tissue, respectively (Child and Tallon, 2022). Therefore, the
membrane concentrations of cannabinoids are likely to reach to
pharmacologically relevant ranges to exert their effects on the
functional properties of LGICs described in this review. However,
the results of studies using concentrations of cannabinoids above 2030 µM may have no pharmacological relevance.
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Conclusion
Cannabinoids have appeared as important modulators of
diverse pathological and physiological processes and intensive
research efforts have examined the efﬁcacy of cannabinoid
antagonist and agonist as therapeutic agents. Although
cannabinoids primarily exert their cellular and organ
system
effects
by
interacting
with
CB1
and
CB2 cannabinoid receptors, in recent years, it has been
shown that not all effects of these agents are mediated by
cannabinoid receptors. Several lines of evidence show that
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